PPARγ and Cognitive Performance
Abstract
:1. Introduction
2. PPARγ and Cognition
PPARγ and BDNF
3. PPARγ and Alzheimer’s Disease
4. PPARγ in Parkinson’s Disease
5. PPARγ in Huntington Disease
6. PPARγ and Autism
7. PPARγ in Schizophrenia
8. Discussion and Conclusions
Funding
Conflicts of Interest
References
- Cristiano, L.; Cimini, A.; Moreno, S.; Ragnelli, A.M.; Paola Cerù, M. Peroxisome proliferator-activated receptors (PPARs) and related transcription factors in differentiating astrocyte cultures. Neuroscience 2005, 131, 577–587. [Google Scholar] [CrossRef] [PubMed]
- Cullingford, T.E.; Bhakoo, K.; Peuchen, S.; Dolphin, C.T.; Patel, R.; Clark, J.B. Distribution of mRNAs Encoding the Peroxisome Proliferator-Activated Receptor α, β, and γ and the Retinoid X Receptor α, β, and γ in Rat Central Nervous System. J. Neurochem. 2002, 70, 1366–1375. [Google Scholar] [CrossRef] [PubMed]
- Moreno, S.; Farioli-Vecchioli, S.; Cerù, M.P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004, 123, 131–145. [Google Scholar] [CrossRef] [PubMed]
- Warden, A.; Truitt, J.; Merriman, M.; Ponomareva, O.; Jameson, K.; Ferguson, L.B.; Mayfield, R.D.; Harris, R.A. Localization of PPAR isotypes in the adult mouse and human brain. Sci. Rep. 2016, 6, 27618. [Google Scholar] [CrossRef] [PubMed]
- Heneka, M.T.; Klockgether, T.; Feinstein, D.L. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J. Neurosci. 2000, 20, 6862–6867. [Google Scholar] [CrossRef]
- Lu, M.; Sarruf, D.A.; Talukdar, S.; Sharma, S.; Li, P.; Bandyopadhyay, G.; Nalbandian, S.; Fan, W.; Gayen, J.R.; Mahata, S.K.; et al. Brain PPAR-γ promotes obesity and is required for the insulin–sensitizing effect of thiazolidinediones. Nat. Med. 2011, 17, 618–622. [Google Scholar] [CrossRef]
- Ryan, K.K.; Li, B.; Grayson, B.E.; Matter, E.K.; Woods, S.C.; Seeley, R.J. A role for central nervous system PPAR-γ in the regulation of energy balance. Nat. Med. 2011, 17, 623–626. [Google Scholar] [CrossRef]
- Williams, J.M.; Thompson, V.L.; Mason-Parker, S.E.; Abraham, W.C.; Tate, W.P. Synaptic activity-dependent modulation of mitochondrial gene expression in the rat hippocampus. Mol. Brain Res. 1998, 60, 50–56. [Google Scholar] [CrossRef]
- Calabresi, P.; Ammassari-Teule, M.; Gubellini, P.; Sancesario, G.; Morello, M.; Centonze, D.; Marfia, G.A.; Saulle, E.; Passino, E.; Picconi, B.; et al. A Synaptic Mechanism Underlying the Behavioral Abnormalities Induced by Manganese Intoxication. Neurobiol. Dis. 2001, 8, 419–432. [Google Scholar] [CrossRef] [Green Version]
- Li, Z.; Jo, J.; Jia, J.-M.; Lo, S.-C.; Whitcomb, D.J.; Jiao, S.; Cho, K.; Sheng, M. Caspase-3 Activation via Mitochondria Is Required for Long-Term Depression and AMPA Receptor Internalization. Cell 2010, 141, 859–871. [Google Scholar] [CrossRef] [Green Version]
- Lu, J.; Ma, S.; Sun, J.; Xia, C.; Liu, C.; Wang, Z.; Zhao, X.; Gao, F.; Gong, Q.; Song, B.; et al. Manganese ferrite nanoparticle micellar nanocomposites as MRI contrast agent for liver imaging. Biomaterials 2009, 30, 2919–2928. [Google Scholar] [CrossRef] [PubMed]
- Burkhalter, J.; Fiumelli, H.; Allaman, I.; Chatton, J.-Y.; Martin, J.-L. Brain-derived neurotrophic factor stimulates energy metabolism in developing cortical neurons. J. Neurosci. 2003, 23, 8212–8220. [Google Scholar] [CrossRef] [PubMed]
- Markham, A.; Cameron, I.; Franklin, P.; Spedding, M. BDNF increases rat brain mitochondrial respiratory coupling at complex I, but not complex II. Eur. J. Neurosci. 2004, 20, 1189–1196. [Google Scholar] [CrossRef] [PubMed]
- Mattson, M.P. Pathways towards and away from Alzheimer’s disease. Nature 2004, 430, 631–639. [Google Scholar] [CrossRef]
- Ekstrom, A.D.; Kahana, M.J.; Caplan, J.B.; Fields, T.A.; Isham, E.A.; Newman, E.L.; Fried, I. Cellular networks underlying human spatial navigation. Nature 2003, 425, 184–188. [Google Scholar] [CrossRef]
- Griffin, R.; Nally, R.; Nolan, Y.; McCartney, Y.; Linden, J.; Lynch, M.A. The age-related attenuation in long-term potentiation is associated with microglial activation. J. Neurochem. 2006, 99, 1263–1272. [Google Scholar] [CrossRef]
- Loane, D.J.; Deighan, B.F.; Clarke, R.M.; Griffin, R.J.; Lynch, A.M.; Lynch, M.A. Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain. Neurobiol. Aging 2009, 30, 920–931. [Google Scholar] [CrossRef]
- Maher, F.O.; Nolan, Y.; Lynch, M.A. Downregulation of IL-4-induced signalling in hippocampus contributes to deficits in LTP in the aged rat. Neurobiol. Aging 2005, 26, 717–728. [Google Scholar] [CrossRef]
- Wang, B.W.; Hok, V.; Della-Chiesa, A.; Callaghan, C.; Barlow, S.; Tsanov, M.; Bechara, R.; Irving, E.; Virley, D.J.; Upton, N.; et al. Rosiglitazone enhances learning, place cell activity, and synaptic plasticity in middle-aged rats. Neurobiol. Aging 2012, 33, 835. [Google Scholar] [CrossRef]
- Yin, C.; Deng, Y.; Liu, Y.; Gao, J.; Yan, L.; Gong, Q. Icariside II Ameliorates Cognitive Impairments Induced by Chronic Cerebral Hypoperfusion by Inhibiting the Amyloidogenic Pathway: Involvement of BDNF/TrkB/CREB Signaling and Up-Regulation of PPARα and PPARγ in Rats. Front. Pharmacol. 2018, 9. [Google Scholar] [CrossRef]
- Farshbaf, M.J.; Ghaedi, K.; Shirani, M.; Nasr-Esfahani, M.H. Peroxisome proliferator activated receptor gamma (PPARγ) as a therapeutic target for improvement of cognitive performance in Fragile-X. Med. Hypotheses 2014, 82, 291–294. [Google Scholar] [CrossRef] [PubMed]
- Bathina, S.; Das, U.N. Brain-derived neurotrophic factor and its clinical implications. Arch. Med. Sci. 2015, 11, 1164–1178. [Google Scholar] [CrossRef] [PubMed]
- Miranda, M.; Morici, J.F.; Zanoni, M.B.; Bekinschtein, P. Brain-Derived Neurotrophic Factor: A Key Molecule for Memory in the Healthy and the Pathological Brain. Front. Cell. Neurosci. 2019, 13, 363. [Google Scholar] [CrossRef] [PubMed]
- Amin, R.H.; Mathews, S.T.; Camp, H.S.; Ding, L.; Leff, T. Selective activation of PPARγ in skeletal muscle induces endogenous production of adiponectin and protects mice from diet-induced insulin resistance. Am. J. Physiol.-Endocrinol. Metab. 2010, 298, E28–E37. [Google Scholar] [CrossRef]
- Kariharan, T.; Nanayakkara, G.; Parameshwaran, K.; Bagasrawala, I.; Ahuja, M.; Abdel-Rahman, E.; Amin, A.T.; Dhanasekaran, M.; Suppiramaniam, V.; Amin, R.H. Central activation of PPAR-gamma ameliorates diabetes induced cognitive dysfunction and improves BDNF expression. Neurobiol. Aging 2015, 36, 1451–1461. [Google Scholar] [CrossRef]
- Kishi, T.; Hirooka, Y.; Sunagawa, K. Telmisartan protects against cognitive decline via up-regulation of brain-derived neurotrophic factor/tropomyosin-related kinase B in hippocampus of hypertensive rats. J. Cardiol. 2012, 60, 489–494. [Google Scholar] [CrossRef] [Green Version]
- Tanzi, R.E.; Bertram, L. Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective. Cell 2005, 120, 545–555. [Google Scholar] [CrossRef]
- Castelli, V.; Benedetti, E.; Antonosante, A.; Catanesi, M.; Pitari, G.; Ippoliti, R.; Cimini, A.; d’Angelo, M. Neuronal Cells Rearrangement During Aging and Neurodegenerative Disease: Metabolism, Oxidative Stress and Organelles Dynamic. Front. Mol. Neurosci. 2019, 12, 132. [Google Scholar] [CrossRef] [Green Version]
- Cai, W.; Yang, T.; Liu, H.; Han, L.; Zhang, K.; Hu, X.; Zhang, X.; Yin, K.-J.; Gao, Y.; Bennett, M.V.L.; et al. Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair. Prog. Neurobiol. 2018, 163–164, 27–58. [Google Scholar] [CrossRef]
- Govindarajulu, M.; Pinky, P.D.; Bloemer, J.; Ghanei, N.; Suppiramaniam, V.; Amin, R. Signaling Mechanisms of Selective PPARγ Modulators in Alzheimer’s Disease. PPAR Res. 2018, 2018, 2010675. [Google Scholar] [CrossRef]
- Vallée, A.; Lecarpentier, Y. Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and Gamma. Front. Neurosci. 2016, 10. [Google Scholar] [CrossRef] [PubMed]
- Pedersen, W.A.; McMillan, P.J.; Kulstad, J.J.; Leverenz, J.B.; Craft, S.; Haynatzki, G.R. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp. Neurol. 2006, 199, 265–273. [Google Scholar] [CrossRef] [PubMed]
- Escribano, L.; Simón, A.-M.; Gimeno, E.; Cuadrado-Tejedor, M.; López de Maturana, R.; García-Osta, A.; Ricobaraza, A.; Pérez-Mediavilla, A.; Del Río, J.; Frechilla, D. Rosiglitazone rescues memory impairment in Alzheimer’s transgenic mice: Mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 2010, 35, 1593–1604. [Google Scholar] [CrossRef] [PubMed]
- Cheng, H.; Shang, Y.; Jiang, L.; Shi, T.; Wang, L. The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer’s disease and mild-to-moderate Alzheimer’s disease: A meta-analysis. Int. J. Neurosci. 2016, 126, 299–307. [Google Scholar] [CrossRef]
- Jahrling, J.B.; Hernandez, C.M.; Denner, L.; Dineley, K.T. PPAR Recruitment to Active ERK during Memory Consolidation Is Required for Alzheimer’s Disease-Related Cognitive Enhancement. J. Neurosci. 2014, 34, 4054–4063. [Google Scholar] [CrossRef]
- Passamonti, L.; Tsvetanov, K.A.; Jones, P.S.; Bevan-Jones, W.R.; Arnold, R.; Borchert, R.J.; Mak, E.; Su, L.; O’Brien, J.T.; Rowe, J.B. Neuroinflammation and Functional Connectivity in Alzheimer’s Disease: Interactive Influences on Cognitive Performance. J. Neurosci. 2019, 39, 7218–7226. [Google Scholar] [CrossRef]
- Mondragón-Rodríguez, S.; Perry, G.; Zhu, X.; Moreira, P.I.; Acevedo-Aquino, M.C.; Williams, S. Phosphorylation of Tau Protein as the Link between Oxidative Stress, Mitochondrial Dysfunction, and Connectivity Failure: Implications for Alzheimer’s Disease. Oxidative Med. Cell. Longev. 2013, 2013, 1–6. [Google Scholar] [CrossRef]
- Heneka, M.T.; Sastre, M.; Dumitrescu-Ozimek, L.; Hanke, A.; Dewachter, I.; Kuiperi, C.; O’Banion, K.; Klockgether, T.; Van Leuven, F.; Landreth, G.E. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 2005, 128, 1442–1453. [Google Scholar] [CrossRef]
- Mandrekar-Colucci, S.; Karlo, J.C.; Landreth, G.E. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer’s disease. J. Neurosci. 2012, 32, 10117–10128. [Google Scholar] [CrossRef]
- Yamanaka, M.; Ishikawa, T.; Griep, A.; Axt, D.; Kummer, M.P.; Heneka, M.T. PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J. Neurosci. 2012, 32, 17321–17331. [Google Scholar] [CrossRef]
- Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G.M.; Cooper, N.R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B.L.; et al. Inflammation and Alzheimer’s disease. Neurobiol. Aging 2000, 21, 383–421. [Google Scholar] [CrossRef]
- Heneka, M.T.; Landreth, G.E. PPARs in the brain. Biochim. Biophys. Acta 2007, 1771, 1031–1045. [Google Scholar] [CrossRef] [PubMed]
- Heneka, M.T.; Wiesinger, H.; Dumitrescu-Ozimek, L.; Riederer, P.; Feinstein, D.L.; Klockgether, T. Neuronal and Glial Coexpression of Argininosuccinate Synthetase and Inducible Nitric Oxide Synthase in Alzheimer Disease. J. Neuropathol. Exp. Neurol. 2001, 60, 906–916. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, S.C.; Zhao, M.-L.; Hirano, A.; Dickson, D.W. Inducible Nitric Oxide Synthase Immunoreactivity in the Alzheimer Disease Hippocampus: Association with Hirano Bodies, Neurofibrillary Tangles, and Senile Plaques. J. Neuropathol. Exp. Neurol. 1999, 58, 1163–1169. [Google Scholar] [CrossRef] [Green Version]
- Vodovotz, Y. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer’s disease. J. Exp. Med. 1996, 184, 1425–1433. [Google Scholar] [CrossRef]
- Kielian, T.; Drew, P.D. Effects of peroxisome proliferator-activated receptor-? agonists on central nervous system inflammation. J. Neurosci. Res. 2003, 71, 315–325. [Google Scholar] [CrossRef]
- Landreth, G. Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer’s disease. Neurobiol. Aging 2001, 22, 937–944. [Google Scholar] [CrossRef]
- in ’t Veld, B.A.; Ruitenberg, A.; Hofman, A.; Launer, L.J.; van Duijn, C.M.; Stijnen, T.; Breteler, M.M.B.; Stricker, B.H.C. Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer’s Disease. New Engl. J. Med. 2001, 345, 1515–1521. [Google Scholar] [CrossRef]
- Lehmann, J.M.; Lenhard, J.M.; Oliver, B.B.; Ringold, G.M.; Kliewer, S.A. Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs. J. Biol. Chem. 1997, 272, 3406–3410. [Google Scholar] [CrossRef]
- Heneka, M.T.; Feinstein, D.L.; Galea, E.; Gleichmann, M.; Wüllner, U.; Klockgether, T. Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J. Neuroimmunol. 1999, 100, 156–168. [Google Scholar] [CrossRef]
- Song, G.J.; Nam, Y.; Jo, M.; Jung, M.; Koo, J.Y.; Cho, W.; Koh, M.; Park, S.B.; Suk, K. A novel small-molecule agonist of PPAR-γ potentiates an anti-inflammatory M2 glial phenotype. Neuropharmacology 2016, 109, 159–169. [Google Scholar] [CrossRef] [PubMed]
- Chawla, A.; Barak, Y.; Nagy, L.; Liao, D.; Tontonoz, P.; Evans, R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 2001, 7, 48–52. [Google Scholar] [CrossRef] [PubMed]
- Heneka, M.T.; Carson, M.J.; El Khoury, J.; Landreth, G.E.; Brosseron, F.; Feinstein, D.L.; Jacobs, A.H.; Wyss-Coray, T.; Vitorica, J.; Ransohoff, R.M.; et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015, 14, 388–405. [Google Scholar] [CrossRef]
- Brown, S.M.; Henning, S.; Wellman, C.L. Mild, short-term stress alters dendritic morphology in rat medial prefrontal cortex. Cereb. Cortex 2005, 15, 1714–1722. [Google Scholar] [CrossRef] [PubMed]
- Obulesu, M.; Lakshmi, M.J. Apoptosis in Alzheimer’s disease: An understanding of the physiology, pathology and therapeutic avenues. Neurochem. Res. 2014, 39, 2301–2312. [Google Scholar] [CrossRef] [PubMed]
- Qin, W.; Haroutunian, V.; Katsel, P.; Cardozo, C.P.; Ho, L.; Buxbaum, J.D.; Pasinetti, G.M. PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch. Neurol. 2009, 66, 352–361. [Google Scholar] [CrossRef] [PubMed]
- Wareski, P.; Vaarmann, A.; Choubey, V.; Safiulina, D.; Liiv, J.; Kuum, M.; Kaasik, A. PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons. J. Biol. Chem. 2009, 284, 21379–21385. [Google Scholar] [CrossRef]
- Chiang, M.-C.; Cheng, Y.-C.; Chen, H.-M.; Liang, Y.-J.; Yen, C.-H. Rosiglitazone promotes neurite outgrowth and mitochondrial function in N2A cells via PPARgamma pathway. Mitochondrion 2014, 14, 7–17. [Google Scholar] [CrossRef]
- Prakash, A.; Kumar, A. Role of nuclear receptor on regulation of BDNF and neuroinflammation in hippocampus of β-amyloid animal model of Alzheimer’s disease. Neurotox Res. 2014, 25, 335–347. [Google Scholar] [CrossRef]
- Marks, J.L.; Porte, D.; Stahl, W.L.; Baskin, D.G. Localization of insulin receptor mRNA in rat brain by in situ hybridization. Endocrinology 1990, 127, 3234–3236. [Google Scholar] [CrossRef]
- Unger, J.W.; Betz, M. Insulin receptors and signal transduction proteins in the hypothalamo-hypophyseal system: A review on morphological findings and functional implications. Histol. Histopathol. 1998, 13, 1215–1224. [Google Scholar] [PubMed]
- Werther, G.A.; Hogg, A.; Oldfield, B.J.; McKinley, M.J.; Figdor, R.; Allen, A.M.; Mendelsohn, F.A. Localization and characterization of insulin receptors in rat brain and pituitary gland using in vitro autoradiography and computerized densitometry. Endocrinology 1987, 121, 1562–1570. [Google Scholar] [CrossRef] [PubMed]
- Zhao, W.; Chen, H.; Xu, H.; Moore, E.; Meiri, N.; Quon, M.J.; Alkon, D.L. Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J. Biol. Chem. 1999, 274, 34893–34902. [Google Scholar] [CrossRef] [PubMed]
- Bloemer, J.; Bhattacharya, S.; Amin, R.; Suppiramaniam, V. Impaired insulin signaling and mechanisms of memory loss. Prog. Mol. Biol. Transl. Sci. 2014, 121, 413–449. [Google Scholar] [PubMed]
- Steen, E.; Terry, B.M.; Rivera, E.J.; Cannon, J.L.; Neely, T.R.; Tavares, R.; Xu, X.J.; Wands, J.R.; de la Monte, S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease--is this type 3 diabetes? J. Alzheimers Dis. 2005, 7, 63–80. [Google Scholar] [CrossRef] [PubMed]
- Hoyer, S.; Lannert, H. Inhibition of the neuronal insulin receptor causes Alzheimer-like disturbances in oxidative/energy brain metabolism and in behavior in adult rats. Ann. N. Y. Acad. Sci. 1999, 893, 301–303. [Google Scholar] [CrossRef]
- Pipatpiboon, N.; Pratchayasakul, W.; Chattipakorn, N.; Chattipakorn, S.C. PPARγ agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets. Endocrinology 2012, 153, 329–338. [Google Scholar] [CrossRef]
- Almasi-Nasrabadi, M.; Javadi-Paydar, M.; Mahdavian, S.; Babaei, R.; Sharifian, M.; Norouzi, A.; Dehpour, A.R. Involvement of NMDA receptors in the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice. Behav. Brain Res. 2012, 231, 138–145. [Google Scholar] [CrossRef]
- Jedrziewski, M.K.; Ewbank, D.C.; Wang, H.; Trojanowski, J.Q. The Impact of Exercise, Cognitive Activities, and Socialization on Cognitive Function: Results From the National Long-Term Care Survey. Am. J. Alzheimers Dis. Other Demen. 2014, 29, 372–378. [Google Scholar] [CrossRef]
- Okonkwo, O.C.; Schultz, S.A.; Oh, J.M.; Larson, J.; Edwards, D.; Cook, D.; Koscik, R.; Gallagher, C.L.; Dowling, N.M.; Carlsson, C.M.; et al. Physical activity attenuates age-related biomarker alterations in preclinical AD. Neurology 2014, 83, 1753–1760. [Google Scholar] [CrossRef] [Green Version]
- Mendiola-Precoma, J.; Berumen, L.C.; Padilla, K.; Garcia-Alcocer, G. Therapies for Prevention and Treatment of Alzheimer’s Disease. BioMed. Res. Int. 2016, 2016, 2589276. [Google Scholar] [CrossRef] [PubMed]
- Wakabayashi, K.; Tanji, K.; Mori, F.; Takahashi, H. The Lewy body in Parkinson’s disease: Molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 2007, 27, 494–506. [Google Scholar] [CrossRef] [PubMed]
- Power, J.H.T.; Barnes, O.L.; Chegini, F. Lewy Bodies and the Mechanisms of Neuronal Cell Death in Parkinson’s Disease and Dementia with Lewy Bodies. Brain Pathol. 2017, 27, 3–12. [Google Scholar] [CrossRef] [PubMed]
- Falcone, R.; Marilena Florio, T.; Giacomo, E.D.; Benedetti, E.; Cristiano, L.; Antonosante, A.; Fidoamore, A.; Massimi, M.; Alecci, M.; Ippoliti, R.; et al. PPARβ/δ and γ in a Rat Model of Parkinson’s Disease: Possible Involvement in PD Symptoms: PPARΒ/δ and γ in a rat model of parkinson’s disease. J. Cell. Biochem. 2015, 116, 844–855. [Google Scholar] [CrossRef] [PubMed]
- Roheger, M.; Kalbe, E.; Liepelt-Scarfone, I. Progression of Cognitive Decline in Parkinson’s Disease. J. Parkinsons Dis. 2018, 8, 183–193. [Google Scholar] [CrossRef]
- Lawson, R.A.; Yarnall, A.J.; Duncan, G.W.; Breen, D.P.; Khoo, T.K.; Williams-Gray, C.H.; Barker, R.A.; Burn, D.J.; ICICLE-PD study group. Stability of mild cognitive impairment in newly diagnosed Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 2017, 88, 648–652. [Google Scholar] [CrossRef] [PubMed]
- Santangelo, G.; Vitale, C.; Picillo, M.; Moccia, M.; Cuoco, S.; Longo, K.; Pezzella, D.; di Grazia, A.; Erro, R.; Pellecchia, M.T.; et al. Mild Cognitive Impairment in newly diagnosed Parkinson’s disease: A longitudinal prospective study. Parkinsonism Relat. Disord. 2015, 21, 1219–1226. [Google Scholar] [CrossRef]
- Hely, M.A.; Reid, W.G.J.; Adena, M.A.; Halliday, G.M.; Morris, J.G.L. The Sydney multicenter study of Parkinson’s disease: The inevitability of dementia at 20 years: Twenty Year Sydney Parkinson’s Study. Mov. Disord. 2008, 23, 837–844. [Google Scholar] [CrossRef]
- King, E.; O’Brien, J.; Donaghy, P.; Williams-Gray, C.H.; Lawson, R.A.; Morris, C.M.; Barnett, N.; Olsen, K.; Martin-Ruiz, C.; Burn, D.; et al. Inflammation in mild cognitive impairment due to Parkinson’s disease, Lewy body disease, and Alzheimer’s disease. Int. J. Geriatr. Psychiatry 2019, 34, 1244–1250. [Google Scholar] [CrossRef]
- Hirsch, E.C.; Hunot, S. Neuroinflammation in Parkinson’s disease: A target for neuroprotection? Lancet Neurol. 2009, 8, 382–397. [Google Scholar] [CrossRef]
- Long-Smith, C.M.; Sullivan, A.M.; Nolan, Y.M. The influence of microglia on the pathogenesis of Parkinson’s disease. Prog. Neurobiol. 2009, 89, 277–287. [Google Scholar] [CrossRef] [PubMed]
- McGeer, P.L.; McGeer, E.G. Glial reactions in Parkinson’s disease. Mov. Disord. 2008, 23, 474–483. [Google Scholar] [CrossRef] [PubMed]
- Stoker, T.B.; Torsney, K.M.; Barker, R.A. Emerging Treatment Approaches for Parkinson’s Disease. Front. Neurosci. 2018, 12, 693. [Google Scholar] [CrossRef] [PubMed]
- Ren, L.; Yi, J.; Yang, J.; Li, P.; Cheng, X.; Mao, P. Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease: A dose–response meta-analysis. Medicine 2018, 97, e12172. [Google Scholar] [CrossRef]
- Samii, A.; Etminan, M.; Wiens, M.O.; Jafari, S. NSAID use and the risk of Parkinson’s disease: Systematic review and meta-analysis of observational studies. Drugs Aging 2009, 26, 769–779. [Google Scholar] [CrossRef]
- Esposito, E.; Di Matteo, V.; Benigno, A.; Pierucci, M.; Crescimanno, G.; Di Giovanni, G. Non-steroidal anti-inflammatory drugs in Parkinson’s disease. Exp. Neurol. 2007, 205, 295–312. [Google Scholar] [CrossRef]
- Randy, L.H.; Guoying, B. Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson’s Disease. Curr. Neuropharmacol. 2007, 5, 35–46. [Google Scholar]
- Dehmer, T.; Heneka, M.T.; Sastre, M.; Dichgans, J.; Schulz, J.B. Protection by pioglitazone in the MPTP model of Parkinson’s disease correlates with IκBα induction and block of NFκB and iNOS activation: PPARg ligand protects against MPTP toxicity. J. Neurochem. 2003, 88, 494–501. [Google Scholar] [CrossRef]
- Breidert, T.; Callebert, J.; Heneka, M.T.; Landreth, G.; Launay, J.M.; Hirsch, E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson’s disease. J. Neurochem. 2002, 82, 615–624. [Google Scholar] [CrossRef]
- Xing, B.; Liu, M.; Bing, G. Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-κB and JNK activation and suppression of COX-2 activity. J. Neuroimmunol. 2007, 192, 89–98. [Google Scholar] [CrossRef]
- Xing, B.; Xin, T.; Hunter, R.; Bing, G. Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. J. Neuroinflamm. 2008, 5, 4. [Google Scholar] [CrossRef] [PubMed]
- Cimini, A.; Benedetti, E.; Cristiano, L.; Sebastiani, P.; D’Amico, M.A.; D’Angelo, B.; Di Loreto, S. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience 2005, 130, 325–337. [Google Scholar] [CrossRef] [PubMed]
- Koppal, T.; Petrova, T.V.; Van Eldik, L.J. Cyclopentenone prostaglandin 15-deoxy-Δ12,14-prostaglandin J2 acts as a general inhibitor of inflammatory responses in activated BV-2 microglial cells. Brain Res. 2000, 867, 115–121. [Google Scholar] [CrossRef]
- Luna-Medina, R.; Cortes-Canteli, M.; Alonso, M.; Santos, A.; Martínez, A.; Perez-Castillo, A. Regulation of Inflammatory Response in Neural Cells in Vitro by Thiadiazolidinones Derivatives through Peroxisome Proliferator-activated Receptor γ Activation. J. Biol. Chem. 2005, 280, 21453–21462. [Google Scholar] [CrossRef]
- Xu, J.; Drew, P.D. Peroxisome Proliferator-Activated Receptor-γ Agonists Suppress the Production of IL-12 Family Cytokines by Activated Glia. J. Immunol. 2007, 178, 1904–1913. [Google Scholar] [CrossRef]
- Joers, V.; Tansey, M.G.; Mulas, G.; Carta, A.R. Microglial phenotypes in Parkinson’s disease and animal models of the disease. Prog. Neurobiol. 2017, 155, 57–75. [Google Scholar] [CrossRef]
- Bernardo, A.; Minghetti, L. PPAR-γ Agonists as Regulators of Microglial Activation and Brain Inflammation. Curr. Pharm. Des. 2006, 12, 93–109. [Google Scholar] [CrossRef]
- Corona, J.C.; Duchen, M.R. PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease. Free Radic. Biol. Med. 2016, 100, 153–163. [Google Scholar] [CrossRef]
- Blesa, J.; Trigo-Damas, I.; Quiroga-Varela, A.; Jackson-Lewis, V.R. Oxidative stress and Parkinson’s disease. Front. Neuroanat. 2015, 9, 91. [Google Scholar] [CrossRef]
- Wei, Z.; Li, X.; Li, X.; Liu, Q.; Cheng, Y. Oxidative Stress in Parkinson’s Disease: A Systematic Review and Meta-Analysis. Front. Mol. Neurosci. 2018, 11, 236. [Google Scholar] [CrossRef]
- Quinn, L.P.; Crook, B.; Hows, M.E.; Vidgeon-Hart, M.; Chapman, H.; Upton, N.; Medhurst, A.D.; Virley, D.J. The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson’s disease through inhibition of monoamine oxidase B. Br. J. Pharmacol. 2008, 154, 226–233. [Google Scholar] [CrossRef] [PubMed]
- Chaturvedi, R.K.; Beal, M.F. PPAR: A therapeutic target in Parkinson’s disease. J. Neurochem. 2008, 106, 506–518. [Google Scholar] [CrossRef] [PubMed]
- Hunter, R.L.; Dragicevic, N.; Seifert, K.; Choi, D.Y.; Liu, M.; Kim, H.-C.; Cass, W.A.; Sullivan, P.G.; Bing, G. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system: LPS effects nigrostriatal mitochondria. J. Neurochem. 2007, 100, 1375–1386. [Google Scholar] [CrossRef] [PubMed]
- Schintu, N.; Frau, L.; Ibba, M.; Caboni, P.; Garau, A.; Carboni, E.; Carta, A.R. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson’s disease. Eur. J. Neurosci. 2009, 29, 954–963. [Google Scholar] [CrossRef] [PubMed]
- Hernandez-Baltazar, D.; Mendoza-Garrido, M.E.; Martinez-Fong, D. Activation of GSK-3β and caspase-3 occurs in Nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine. PLoS ONE 2013, 8, e70951. [Google Scholar] [CrossRef] [PubMed]
- Tatton, W.G.; Chalmers-Redman, R.; Brown, D.; Tatton, N. Apoptosis in Parkinson’s disease: Signals for neuronal degradation. Ann. Neurol. 2003, 53, S61–S72. [Google Scholar] [CrossRef] [PubMed]
- Barbiero, J.K.; Santiago, R.M.; Persike, D.S.; da Silva Fernandes, M.J.; Tonin, F.S.; da Cunha, C.; Lucio Boschen, S.; Lima, M.M.S.; Vital, M.A.B.F. Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine. Behav. Brain Res. 2014, 274, 390–399. [Google Scholar] [CrossRef]
- Sulzer, D.; Surmeier, D.J. Neuronal vulnerability, pathogenesis, and Parkinson’s disease: Neuronal Vulnerability, Pathogenesis, and PD. Mov. Disord. 2013, 28, 41–50. [Google Scholar] [CrossRef]
- Dias, V.; Junn, E.; Mouradian, M.M. The role of oxidative stress in Parkinson’s disease. J. Parkinsons Dis. 2013, 3, 461–491. [Google Scholar]
- Puspita, L.; Chung, S.Y.; Shim, J.-W. Oxidative stress and cellular pathologies in Parkinson’s disease. Mol. Brain 2017, 10, 53. [Google Scholar] [CrossRef]
- Chen, C.; Turnbull, D.M.; Reeve, A.K. Mitochondrial Dysfunction in Parkinson’s Disease-Cause or Consequence? Biology 2019, 8, 38. [Google Scholar] [CrossRef] [PubMed]
- Jung, T.W.; Lee, J.Y.; Shim, W.S.; Kang, E.S.; Kim, S.K.; Ahn, C.W.; Lee, H.C.; Cha, B.S. Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity. Biochem. Biophys. Res. Commun. 2006, 340, 221–227. [Google Scholar] [CrossRef] [PubMed]
- De Nuccio, C.; Bernardo, A.; Cruciani, C.; De Simone, R.; Visentin, S.; Minghetti, L. Peroxisome proliferator activated receptor-γ agonists protect oligodendrocyte progenitors against tumor necrosis factor-alpha-induced damage: Effects on mitochondrial functions and differentiation. Exp. Neurol. 2015, 271, 506–514. [Google Scholar] [CrossRef] [PubMed]
- Corona, J.C.; de Souza, S.C.; Duchen, M.R. PPARγ activation rescues mitochondrial function from inhibition of complex I and loss of PINK1. Exp. Neurol. 2014, 253, 16–27. [Google Scholar] [CrossRef]
- Lecca, D.; Nevin, D.K.; Mulas, G.; Casu, M.A.; Diana, A.; Rossi, D.; Sacchetti, G.; Carta, A.R. Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice. Neuroscience 2015, 302, 23–35. [Google Scholar] [CrossRef]
- Kumar, P.; Kaundal, R.K.; More, S.; Sharma, S.S. Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson’s disease. Behav. Brain Res. 2009, 197, 398–403. [Google Scholar] [CrossRef]
- Tamtaji, O.R.; Taghizadeh, M.; Aghadavod, E.; Mafi, A.; Dadgostar, E.; Daneshvar Kakhaki, R.; Abolhassani, J.; Asemi, Z. The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression related to inflammation, insulin and lipid in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Clin. Neurol. Neurosurg. 2019, 176, 116–121. [Google Scholar] [CrossRef]
- Oliveira de Carvalho, A.; Filho, A.S.S.; Murillo-Rodriguez, E.; Rocha, N.B.; Carta, M.G.; Machado, S. Physical Exercise For Parkinson’s Disease: Clinical And Experimental Evidence. Clin. Pract. Epidemiol. Ment. Health 2018, 14, 89–98. [Google Scholar] [CrossRef]
- Castelli, V.; Grassi, D.; Bocale, R.; d’Angelo, M.; Antonosante, A.; Cimini, A.; Ferri, C.; Desideri, G. Diet and Brain Health: Which Role for Polyphenols? Curr. Pharm. Des. 2018, 24, 227–238. [Google Scholar] [CrossRef]
- Martin, J.B.; Gusella, J.F. Huntington’s disease. Pathogenesis and management. N. Engl. J. Med. 1986, 315, 1267–1276. [Google Scholar]
- Middleton, F.A.; Strick, P.L. Basal ganglia and cerebellar loops: Motor and cognitive circuits. Brain Res. Brain Res. Rev. 2000, 31, 236–250. [Google Scholar] [CrossRef]
- Di Maio, L.; Squitieri, F.; Napolitano, G.; Campanella, G.; Trofatter, J.A.; Conneally, P.M. Suicide risk in Huntington’s disease. J. Med. Genet. 1993, 30, 293–295. [Google Scholar] [CrossRef] [PubMed]
- André, V.M.; Cepeda, C.; Levine, M.S. Dopamine and Glutamate in Huntington’s Disease: A Balancing Act: Dopamine-Glutamate Balance in Huntington’s Disease. CNS Neurosci. Ther. 2010, 16, 163–178. [Google Scholar] [CrossRef] [PubMed]
- Chiang, M.-C.; Chen, C.-M.; Lee, M.-R.; Chen, H.-W.; Chen, H.-M.; Wu, Y.-S.; Hung, C.-H.; Kang, J.-J.; Chang, C.-P.; Chang, C.; et al. Modulation of energy deficiency in Huntington’s disease via activation of the peroxisome proliferator-activated receptor gamma. Hum. Mol. Genet. 2010, 19, 4043–4058. [Google Scholar] [CrossRef]
- Jin, J.; Albertz, J.; Guo, Z.; Peng, Q.; Rudow, G.; Troncoso, J.C.; Ross, C.A.; Duan, W. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington’s disease. J. Neurochem. 2013, 125, 410–419. [Google Scholar] [CrossRef]
- Mishra, J.; Chaudhary, T.; Kumar, A. Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: Targeting PPARγ and HDAC pathways. Neurotox. Res. 2014, 26, 130–151. [Google Scholar] [CrossRef]
- Sadri-Vakili, G.; Cha, J.-H.J. Histone deacetylase inhibitors: A novel therapeutic approach to Huntington’s disease (complex mechanism of neuronal death). Curr. Alzheimer Res. 2006, 3, 403–408. [Google Scholar] [CrossRef]
- Langley, B.; Gensert, J.M.; Beal, M.F.; Ratan, R.R. Remodeling chromatin and stress resistance in the central nervous system: Histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr. Drug Targets CNS Neurol. Disord. 2005, 4, 41–50. [Google Scholar] [CrossRef]
- Schwarcz, R.; Guidetti, P.; Sathyasaikumar, K.V.; Muchowski, P.J. Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington’s disease. Prog. Neurobiol. 2010, 90, 230–245. [Google Scholar] [CrossRef]
- Kalonia, H.; Kumar, P.; Kumar, A. Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: Possible role of peroxisome proliferator activated receptor-ϒ (PPARϒ) in Huntington’s disease. Pharmacol. Biochem. Behav. 2010, 96, 115–124. [Google Scholar] [CrossRef]
- Furtado, J.C.S.; Mazurek, M.F. Behavioral Characterization of Quinolinate-Induced Lesions of the Medial Striatum: Relevance for Huntington’s Disease. Exp. Neurol. 1996, 138, 158–168. [Google Scholar] [CrossRef]
- Samadi, P.; Boutet, A.; Rymar, V.V.; Rawal, K.; Maheux, J.; Kvann, J.-C.; Tomaszewski, M.; Beaubien, F.; Cloutier, J.F.; Levesque, D.; et al. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington’s disease: BDNF expression, behavior and striatum morphology. Genes Brain Behav. 2013, 12, 108–124. [Google Scholar] [CrossRef] [PubMed]
- Velusamy, T.; Panneerselvam, A.S.; Purushottam, M.; Anusuyadevi, M.; Pal, P.K.; Jain, S.; Essa, M.M.; Guillemin, G.J.; Kandasamy, M. Protective Effect of Antioxidants on Neuronal Dysfunction and Plasticity in Huntington’s Disease. Oxid. Med. Cell Longev. 2017, 2017, 3279061. [Google Scholar] [CrossRef] [PubMed]
- Vahia, V.N. Diagnostic and statistical manual of mental disorders 5: A quick glance. Indian J. Psychiatry 2013, 55, 220–223. [Google Scholar] [CrossRef] [PubMed]
- Mirza, R.; Sharma, B. Beneficial effects of pioglitazone, a selective peroxisome proliferator-activated receptor-γ agonist in prenatal valproic acid-induced behavioral and biochemical autistic like features in Wistar rats. Int. J. Dev. Neurosci. 2019, 76, 6–16. [Google Scholar] [CrossRef] [PubMed]
- Mirza, R.; Sharma, B. A selective peroxisome proliferator-activated receptor-γ agonist benefited propionic acid induced autism-like behavioral phenotypes in rats by attenuation of neuroinflammation and oxidative stress. Chem. Biol. Interact. 2019, 311, 108758. [Google Scholar] [CrossRef] [PubMed]
- Tontonoz, P.; Spiegelman, B.M. Fat and Beyond: The Diverse Biology of PPARγ. Annu. Rev. Biochem. 2008, 77, 289–312. [Google Scholar] [CrossRef] [PubMed]
- Pilipović, K.; Župan, Ž.; Dolenec, P.; Mršić-Pelčić, J.; Župan, G. A single dose of PPARγ agonist pioglitazone reduces cortical oxidative damage and microglial reaction following lateral fluid percussion brain injury in rats. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2015, 59, 8–20. [Google Scholar] [CrossRef]
- Khalaj, M.; Saghazadeh, A.; Shirazi, E.; Shalbafan, M.-R.; Alavi, K.; Shooshtari, M.H.; Laksari, F.Y.; Hosseini, M.; Mohammadi, M.-R.; Akhondzadeh, S. Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial. J. Psychiatr. Res. 2018, 103, 104–111. [Google Scholar] [CrossRef]
- Noriega, D.B.; Savelkoul, H.F.J. Immune dysregulation in autism spectrum disorder. Eur. J. Pediatrics 2014, 173, 33–43. [Google Scholar] [CrossRef]
- Gładysz, D.; Krzywdzińska, A.; Hozyasz, K.K. Immune Abnormalities in Autism Spectrum Disorder—Could They Hold Promise for Causative Treatment? Mol. Neurobiol. 2018, 55, 6387–6435. [Google Scholar] [CrossRef] [PubMed]
- Boris, M.; Kaiser, C.C.; Goldblatt, A.; Elice, M.W.; Edelson, S.M.; Adams, J.B.; Feinstein, D.L. Effect of pioglitazone treatment on behavioral symptoms in autistic children. J. Neuroinflamm. 2007, 4, 3. [Google Scholar] [CrossRef] [PubMed]
- Ghaleiha, A.; Rasa, S.M.; Nikoo, M.; Farokhnia, M.; Mohammadi, M.-R.; Akhondzadeh, S. A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism. Psychiatry Res. 2015, 229, 181–187. [Google Scholar] [CrossRef]
- Emanuele, E.; Lossano, C.; Politi, P.; Barale, F. Pioglitazone as a therapeutic agent in autistic spectrum disorder. Med. Hypotheses 2007, 69, 699. [Google Scholar] [CrossRef]
- Zdravkovic, V.; Hamilton, J.K.; Daneman, D.; Cummings, E.A. Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes. J. Pediatrics 2006, 149, 845–849. [Google Scholar] [CrossRef] [PubMed]
- Barone, R.; Rizzo, R.; Tabbì, G.; Malaguarnera, M.; Frye, R.E.; Bastin, J. Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum Disorder. Int. J. Mol. Sci. 2019, 20, 1878. [Google Scholar] [CrossRef] [PubMed]
- Valton, V.; Romaniuk, L.; Douglas Steele, J.; Lawrie, S.; Seriès, P. Comprehensive review: Computational modelling of schizophrenia. Neurosci. Biobehav. Rev. 2017, 83, 631–646. [Google Scholar] [CrossRef] [Green Version]
- Peitl, V.; Štefanović, M.; Karlović, D. Depressive symptoms in schizophrenia and dopamine and serotonin gene polymorphisms. Prog. Neuropsychopharmacol. Biol. Psychiatry 2017, 77, 209–215. [Google Scholar] [CrossRef]
- Zhang, Y.; Fang, X.; Fan, W.; Tang, W.; Cai, J.; Song, L.; Zhang, C. Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study. Psychopharmacology 2018, 235, 1191–1198. [Google Scholar] [CrossRef]
- Zhao, G.; Zhang, C.; Chen, J.; Su, Y.; Zhou, R.; Wang, F.; Xia, W.; Huang, J.; Wang, Z.; Hu, Y.; et al. Ratio of mBDNF to proBDNF for Differential Diagnosis of Major Depressive Disorder and Bipolar Depression. Mol. Neurobiol. 2017, 54, 5573–5582. [Google Scholar] [CrossRef]
- Martis, L.; Wiborg, O.; Holmes, M.C.; Harris, A.P. BDNF+/− rats exhibit depressive phenotype and altered expression of genes relevant in mood disorders. Genes, Brain Behav. 2018, 18, e12546. [Google Scholar] [CrossRef] [PubMed]
- Wysokiński, A. Serum levels of brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) in depressed patients with schizophrenia. Nord. J. Psychiatry 2016, 70, 267–271. [Google Scholar] [CrossRef]
- McGrory, C.L.; Ryan, K.M.; Kolshus, E.; Finnegan, M.; McLoughlin, D.M. Peripheral blood SIRT1 mRNA levels in depression and treatment with electroconvulsive therapy. Eur. Neuropsychopharmacol. 2018, 28, 1015–1023. [Google Scholar] [CrossRef] [PubMed]
- Abe-Higuchi, N.; Uchida, S.; Yamagata, H.; Higuchi, F.; Hobara, T.; Hara, K.; Kobayashi, A.; Watanabe, Y. Hippocampal Sirtuin 1 Signaling Mediates Depression-like Behavior. Biol. Psychiatry 2016, 80, 815–826. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hurley, L.L.; Akinfiresoye, L.; Kalejaiye, O.; Tizabi, Y. Antidepressant effects of resveratrol in an animal model of depression. Behav. Brain Res. 2014, 268, 1–7. [Google Scholar] [CrossRef] [Green Version]
- Chen, D.C.; Wang, J.; Wang, B.; Yang, S.C.; Zhang, C.X.; Zheng, Y.L.; Li, Y.L.; Wang, N.; Yang, K.B.; Xiu, M.H.; et al. Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: Relationship to clinical phenotypes. Psychopharmacology 2009, 207, 375–380. [Google Scholar] [CrossRef]
- Zocchi, L.; Sassone-Corsi, P. SIRT1-mediated deacetylation of MeCP2 contributes to BDNF expression. Epigenetics 2012, 7, 695–700. [Google Scholar] [CrossRef] [Green Version]
- Nimmagadda, V.K.; Bever, C.T.; Vattikunta, N.R.; Talat, S.; Ahmad, V.; Nagalla, N.K.; Trisler, D.; Judge, S.I.V.; Royal, W.; Chandrasekaran, K.; et al. Overexpression of SIRT1 Protein in Neurons Protects against Experimental Autoimmune Encephalomyelitis through Activation of Multiple SIRT1 Targets. J. Immunol. 2013, 190, 4595–4607. [Google Scholar] [CrossRef] [Green Version]
- Shen, J.; Li, Y.; Qu, C.; Xu, L.; Sun, H.; Zhang, J. The enriched environment ameliorates chronic unpredictable mild stress-induced depressive-like behaviors and cognitive impairment by activating the SIRT1/miR-134 signaling pathway in hippocampus. J. Affect. Disord. 2019, 248, 81–90. [Google Scholar] [CrossRef]
- Chen, L.-X.; Qi, Z.; Shao, Z.-J.; Li, S.-S.; Qi, Y.-L.; Gao, K.; Liu, S.-X.; Li, Z.; Sun, Y.-S.; Li, P.-Y. Study on Antidepressant Activity of Pseudo-Ginsenoside HQ on Depression Like Behavior in Mice. Molecules 2019, 24, 870. [Google Scholar] [CrossRef]
- Yi, Z.; Fan, X.; Wang, J.; Liu, D.; Freudenreich, O.; Goff, D.; Henderson, D.C. Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: A pilot study. Psychiatry Res. 2012, 200, 79–82. [Google Scholar] [CrossRef] [PubMed]
- Watson, G.S.; Craft, S. The Role of Insulin Resistance in the Pathogenesis of Alzheimer’s Disease: Implications for Treatment. CNS Drugs 2003, 17, 27–45. [Google Scholar] [CrossRef] [PubMed]
- Smith, R.C.; Jin, H.; Li, C.; Bark, N.; Shekhar, A.; Dwivedi, S.; Mortiere, C.; Lohr, J.; Hu, Q.; Davis, J.M. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: A randomized double-blind study. Schizophr. Res. 2013, 143, 18–24. [Google Scholar] [CrossRef] [PubMed]
- Schoepf, D.; Potluri, R.; Uppal, H.; Natalwala, A.; Narendran, P.; Heun, R. Type-2 diabetes mellitus in schizophrenia: Increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up. Eur. Psychiatry 2012, 27, 33–42. [Google Scholar] [CrossRef] [PubMed]
- Iranpour, N.; Zandifar, A.; Farokhnia, M.; Goguol, A.; Yekehtaz, H.; Khodaie-Ardakani, M.-R.; Salehi, B.; Esalatmanesh, S.; Zeionoddini, A.; Mohammadinejad, P.; et al. The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: A double-blind and placebo-controlled trial. Hum. Psychopharmacol. 2016, 31, 103–112. [Google Scholar] [CrossRef]
- García-Bueno, B.; Pérez-Nievas, B.G.; Leza, J.C. Is there a role for the nuclear receptor PPARγ in neuropsychiatric diseases? Int. J. Neuropsychopharmacol. 2010, 13, 1411–1429. [Google Scholar] [CrossRef]
- García-Bueno, B.; Madrigal, J.L.M.; Lizasoain, I.; Moro, M.A.; Lorenzo, P.; Leza, J.C. The anti-inflammatory prostaglandin 15d-PGJ2 decreases oxidative/nitrosative mediators in brain after acute stress in rats. Psychopharmacology 2005, 180, 513–522. [Google Scholar] [CrossRef]
- Brodbeck, J.; Balestra, M.E.; Saunders, A.M.; Roses, A.D.; Mahley, R.W.; Huang, Y. Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons. Proc. Natl. Acad. Sci. USA 2008, 105, 1343–1346. [Google Scholar] [CrossRef] [Green Version]
- Jou, S.-H.; Chiu, N.-Y.; Liu, C.-S. Mitochondrial dysfunction and psychiatric disorders. Chang Gung Med. J. 2009, 32, 370–379. [Google Scholar]
- Rollins, B.; Martin, M.V.; Sequeira, P.A.; Moon, E.A.; Morgan, L.Z.; Watson, S.J.; Schatzberg, A.; Akil, H.; Myers, R.M.; Jones, E.G.; et al. Mitochondrial variants in schizophrenia, bipolar disorder, and major depressive disorder. PLoS ONE 2009, 4, e4913. [Google Scholar] [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
d’Angelo, M.; Castelli, V.; Catanesi, M.; Antonosante, A.; Dominguez-Benot, R.; Ippoliti, R.; Benedetti, E.; Cimini, A. PPARγ and Cognitive Performance. Int. J. Mol. Sci. 2019, 20, 5068. https://doi.org/10.3390/ijms20205068
d’Angelo M, Castelli V, Catanesi M, Antonosante A, Dominguez-Benot R, Ippoliti R, Benedetti E, Cimini A. PPARγ and Cognitive Performance. International Journal of Molecular Sciences. 2019; 20(20):5068. https://doi.org/10.3390/ijms20205068
Chicago/Turabian Styled’Angelo, Michele, Vanessa Castelli, Mariano Catanesi, Andrea Antonosante, Reyes Dominguez-Benot, Rodolfo Ippoliti, Elisabetta Benedetti, and Annamaria Cimini. 2019. "PPARγ and Cognitive Performance" International Journal of Molecular Sciences 20, no. 20: 5068. https://doi.org/10.3390/ijms20205068